[Video] Two Additional MariMed Dispensaries Expected To Come Online Over The Next 2 Months
In a world where some cannabis multi-state operators pare down operations, MariMed, Inc.
Madison Metals Announces Novel Decentralized Uranium-Backed NFT To Challenge Forward Contract Markets
Madison Metals (OTC: MMTLF) Executive Chairman and CEO, Duane Parnham, has always been known as an innovator in the mining space. His latest gambit linking pounds-in-the-ground with non-fungible tokens (NFTs) is his latest idea which is attracting attention in the generally-stodgy world of uranium mining.
MariMed Inc.: Existing Assets Have The Ability To Generate Over $350 million In Revenue Over Time
On August 8, MariMed, Inc. (OTC: MRMD) delivered second quarter 2022 financial results near the beginning of U.S. cannabis earnings season.
Cantor Analayst Pablo Zuanic Believes SAFE Banking Now “The Worst Case Scenario” in 2022
In perhaps a sign that incremental progress on federal cannabis reform is afoot, some Wall Street analysts are increasingly coming around on the idea that reform can happen this year. Cantor Fitzgerald analyst Pablo Zuanic, a noted skeptic on SAFE Banking, now believes the legislation has a real chance of passing this year.
MariMed Inc: Among A Select Few U.S. Cannabis Operators Generating Free Cash Flow And Positive Net Income
In a world where many U.S. cannabis multi-state operators (MSOs) laud the their ability to generate positive Adjusted EBITDA, MariMed, Inc. (OTC: MRMD) goes a couple of steps further.
Cathie Wood’s ARK Genomic Revolution ETF Increases Stake In Atai Life Sciences To Record Highs
After a pause in the purchase of atai Life Sciences N.V. (NASDAQ:ATAI) shares, Cathie Wood’s ARK Genomic Revolution ETF is back on the bid. The actively…
Efficacy Of Pfizer’s Paxlovid COVID Drug Crashes, According To New NIH-Funded Study
A new National Institutes of Health (NIH) funded study sheds new light on the waning effectiveness of Pfizer’s (NYSE: PFE) Paxlovid to prevent patient hospitalizations due to COVID.
Revive Therapeutics Moves On Step Closer In COVID Trial By Submitting Data Access Plan To The FDA
It was an expected step, but a notable one nonetheless. Revive Therapeutics Ltd.(OTC: RVVTF) revealed they have submitted their Data Access Plan to the U.S. Food & Drug Administration (FDA).
Revive Therapeutics: Positive Comments From The FDA Regarding Primary Endpoint Change
The outlook for Revive Therapeutics Ltd. (OTC: RVVTF) Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19 got a little brighter on Thursday.
atai Life Sciences: Unparalleled Diversification With 10 Psychedelic Compounds Going Into Clinical Trials In 2022
In the speculative world of ‘psychedelic’ biotech, companies that are under-capitalized or lacking pipeline diversity face an uphill battle to reach the finish line.